526 results on '"Walker, Paul R."'
Search Results
2. Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma
3. Radio-chemotherapy of glioblastoma cells promotes phagocytosis by macrophages in vitro
4. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
5. Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages
6. Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models
7. How to outsmart the cold tumor microenvironment: Design of STING ligand nanoparticles for improved cancer immunotherapy
8. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models
9. Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma
10. PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma
11. Radio-chemotherapy of glioblastoma cells promotes phagocytosis by macrophages in vitro
12. Immunotherapy: remember the host
13. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer
14. Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer
15. Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting
16. Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells
17. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer
18. Peptides as cancer vaccines
19. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort
20. Induction treatment in operable non-small cell lung cancer: the immune oncology era unfolds
21. Local Radiotherapy Intensification for Locally Advanced Non–small-cell Lung Cancer – A Call to Arms
22. Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines
23. Faculty Opinions recommendation of Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors.
24. Supplementary Figure 2 from Immune Infiltration of Spontaneous Mouse Astrocytomas Is Dominated by Immunosuppressive Cells from Early Stages of Tumor Development
25. Data from Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell–Mediated Antitumor Immunity
26. Supplementary Figure Legends from Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell–Mediated Antitumor Immunity
27. Supplementary Figure 3 from Immune Infiltration of Spontaneous Mouse Astrocytomas Is Dominated by Immunosuppressive Cells from Early Stages of Tumor Development
28. Data from Preferential Expression of Very Late Antigen-4 on Type 1 CTL Cells Plays a Critical Role in Trafficking into Central Nervous System Tumors
29. Supplementary Figure Legends 1-5 from Immune Infiltration of Spontaneous Mouse Astrocytomas Is Dominated by Immunosuppressive Cells from Early Stages of Tumor Development
30. Supplementary Figure 5 from Immune Infiltration of Spontaneous Mouse Astrocytomas Is Dominated by Immunosuppressive Cells from Early Stages of Tumor Development
31. Supplementary Figures S1-S7 from Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell–Mediated Antitumor Immunity
32. Supplementary Figures 1-3 from Preferential Expression of Very Late Antigen-4 on Type 1 CTL Cells Plays a Critical Role in Trafficking into Central Nervous System Tumors
33. Supplementary Figure 1 from Immune Infiltration of Spontaneous Mouse Astrocytomas Is Dominated by Immunosuppressive Cells from Early Stages of Tumor Development
34. Supplementary Figure 4 from Immune Infiltration of Spontaneous Mouse Astrocytomas Is Dominated by Immunosuppressive Cells from Early Stages of Tumor Development
35. Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
36. Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models
37. Case Report: Peripheral blood T cells and inflammatory molecules in lung cancer patients with immune checkpoint inhibitor-induced thyroid dysfunction: Case studies and literature review
38. Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC
39. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition
40. Weighing Projections of Physical Decline in Lung Cancer Surgery Decisions
41. Synthesis, Formulation and Characterization of Immunotherapeutic Glycosylated Dendrimer/cGAMP Complexes for CD206 Targeted Delivery to M2 Macrophages in Cold Tumors
42. Faculty Opinions recommendation of Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice.
43. Plasma Cell-free RNA PD-L1 Expression and Overall Survival of Immune Checkpoint Inhibitor Therapy in Advanced Non-Small Cell Lung Cancer
44. Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort
45. Correlation of clinical outcomes with programmed death ligand-1 expression on liquid biopsy.
46. Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
47. Harnessing T-Cell Immunity to Target Brain Tumors
48. Faculty Opinions recommendation of Antigen cross-presentation in young tumor-bearing hosts promotes CD8+ T cell terminal differentiation.
49. Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition
50. Faculty Opinions recommendation of Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive transfer with tumor-infiltrating lymphocytes in melanoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.